0001964738-26-000022
SEC filingSolventum reported Q1 2026 GAAP diluted EPS of $0.07 and adjusted diluted EPS of $1.48 (+10.6% YoY), with $2.0 billion in sales (−3.0% reported, +2.1% organic), while affirming full-year 2026 organic sales growth, adjusted EPS, and free cash flow guidance.
Solventum’s Q1 2026 results reflect a pronounced divergence between GAAP and Non-GAAP performance, driven overwhelmingly by separation-related costs following its spin-off from 3M. While GAAP net income collapsed 90.5% to $13 million and GAAP EPS fell to $0.07, adjusted EPS rose 10.6% to $1.48 — demonstrating core operational improvement beneath significant one-time charges. Organic sales growth of +2.1% was broad-based across all five reportable segments, with Health Information Systems (+4.7%) and Dental Solutions (+3.4%) outpacing others, validating commercial execution and portfolio strength post-separation. Margin dynamics show resilience: adjusted operating income margin declined only 20 bps to 19.5%, supported by programmatic savings and mix benefits, partially offset by tariffs and inflation. The sharp deterioration in GAAP operating income margin (down 330 bps to 4.0%) underscores the magnitude of separation and restructuring expenses embedded in GAAP results. Cash flow remains under pressure — operating cash flow was $(189) million and free cash flow $(273) million — explicitly attributed to separation activities, transition agreement exit payments, and seasonal factors. Management reaffirmed full-year guidance, notably positioning adjusted EPS 'toward the high end' of $6.40–$6.60, which signals confidence in sustained execution and margin recovery as separation costs normalize. The opening of the Eagan R&D center and Brookings manufacturing expansion further reinforce Solventum’s strategic focus on innovation velocity and supply chain scale — tangible enablers of its long-range plan.